Document Detail


Viral vector-mediated RNA interference.
MedLine Citation:
PMID:  20620113     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
RNA interference (RNAi) is a powerful gene silencing mechanism that if properly harnessed has the potential to revolutionize medical interventions. Delivery of inhibitory RNAs to target tissues needs to be safe, efficient, and for many diseases, long-lasting, in order to exploit this endogenous mechanism for therapeutic purposes. Viral vector systems, based on adeno-associated viruses and lentiviruses, are ideally suited to mediate RNAi because they can safely transduce a wide range of tissues and provide sustained levels of gene expression. There are now many examples of the use of viral vector-mediated RNAi to inhibit gene expression in animal models of disease, and in many cases proof-of-principle has been demonstrated. The efficient delivery of RNAi has also uncovered a number of concerns that raise questions regarding the clinical application of this technology, including off-target effects, innate immune responses, and alterations in the endogenous microRNA (miRNA) pathway. However, over the past several years, work has been done to address these problems and a number of solutions are now being implemented to mitigate these potential risks. With a deeper understanding of RNAi and continued progress in designing RNAi effectors, viral vector-mediated RNAi has the potential to change the way many diseases are treated.
Authors:
Linda B Couto; Katherine A High
Related Documents :
25020303 - P576regulatory analysis of the 4q25 atrial fibrillation risk locus.
2482783 - Differential gene expression during mouse spermatogenesis.
22846753 - Prenatal and early-life exposures alter expression of innate immunity genes: the pastur...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2010-07-09
Journal Detail:
Title:  Current opinion in pharmacology     Volume:  10     ISSN:  1471-4973     ISO Abbreviation:  Curr Opin Pharmacol     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-20     Completed Date:  2011-01-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100966133     Medline TA:  Curr Opin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  534-42     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Ltd. All rights reserved.
Affiliation:
Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenoviridae / genetics
Gene Therapy*
Genetic Vectors*
Humans
Lentivirus / genetics
MicroRNAs / genetics
RNA Interference*
RNA, Small Interfering / genetics,  metabolism
Grant Support
ID/Acronym/Agency:
//Howard Hughes Medical Institute
Chemical
Reg. No./Substance:
0/MicroRNAs; 0/RNA, Small Interfering

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Isolated right ventricular infarct presenting as ventricular fibrillation arrest and confirmed by de...
Next Document:  Neutrophil kinetics in health and disease.